Get the Stockscreener App
0.5379
1.30%
-0.0071
Evogene Ltd stock is traded at $0.5379, with a volume of 62,828.
It is down -1.30% in the last 24 hours and down -17.25% over the past month.
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the industrial segment, followed by Agriculture.
See More
Previous Close:
$0.545
Open:
$0.54005
24h Volume:
62,828
Relative Volume:
0.04
Market Cap:
$8.50M
Revenue:
$1.84M
Net Income/Loss:
$-17.51M
P/E Ratio:
-0.3884
EPS:
-1.3849
Net Cash Flow:
$-17.30M
1W Performance:
-2.13%
1M Performance:
-17.25%
6M Performance:
-35.81%
1Y Performance:
-55.17%
1-Day Range:
$0.5228
$0.5451
1-Week Range:
$0.51
$0.55
52-Week Range:
$0.37
$1.50
Evogene Ltd Stock (EVGN) Company Profile
Compare EVGN vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVGN
Evogene Ltd
|
0.5379 | 8.86M | 1.84M | -17.51M | -17.30M | -1.3849 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Evogene Ltd Stock (EVGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-21 | Initiated | ROTH Capital | Buy |
| Jul-29-21 | Initiated | Aegis Capital | Buy |
| Dec-01-20 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-16-13 | Initiated | Oppenheimer | Outperform |
Evogene Ltd Stock (EVGN) Latest News
Evogene (EVGN) Momentum: Ends Higher by 3.14% at $0.60 on the Day; Next Session: $0.57 and $0.63 Define the Nearby Reference Levels for the Current SessionMoney Flow - dars.gov.et
Evogene Ltd. Q2 2026 Earnings Call Summary - Yahoo Finance
Evogene | 6-K: Report of foreign private issuer (related to financial reporting) - Moomoo
Evogene earnings beat by $0.15, revenue topped estimates - Investing.com India
Evogene Q2 2026 Deep Dive: EPS Beats, Revenue Down 35% - AlphaStreet
Teleconferência de Resultados do 2T26 da Evogene (EVGN): Prejuízo Diminui com Expansão da ChemPass AI - TradingKey
Evogene Q2 2026: Loss Narrows 50.0% to -$0.14/Share, Revenue Down 35% - AlphaStreet
Earnings call transcript: Evogene narrows Q2 2026 loss as shares fall 7.8% - Investing.com Nigeria
Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation - Global Agriculture
EVGN: Q2 net loss down 62% year-over-year as AI-driven focus delivers operational and financial gains - TradingView
EVGN: Q2 2026 net loss fell 62% year-over-year as AI-driven transformation boosted efficiency - TradingView
Evogene: Q2 Earnings Snapshot - theheraldreview.com
Evogene Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Evogene Q2 Results: EPS misses estimate, sales fall 61% YoY - scanx.trade
Evogene Q2 2026 Earnings: Net Loss Narrows Despite Lower Revenue - TradingKey
Evogene Reports Second Quarter and First Half 2026 Financial Results - PR Newswire
EVOGENE ($EVGN) Releases Q2 2026 Earnings - Moomoo
Evogene (EVGN) cuts staff to 38 as it overhauls into AI-driven chemistry - Stock Titan
Earnings To Watch: Evogene Ltd (EVGN) Q2 2026 -- GF Value Sees 15% Downside - Yahoo Finance
Freightos Names Yaron Eldad as Chief Financial Officer - marketscreener.com
EVGN Q2'26 Earnings: EPS estimate is (0.27) USD - TradingView
Armistice Capital (EVGN) discloses 4.99% beneficial stake in Evogene shares - Stock Titan
Evogene chairman to address dissident shareholder issues in Aug 18 earnings call - Pluang
Evogene Chairman Joins Company Results Call on August 18 - Stock Titan
Why Did EVGN Shares Drop More Than 14% Today? - Stocktwits
Evogene Ltd. (EVGN) investors lift beneficial stake to 19.35% of shares - Stock Titan
Evogene (EVGN): Director Leon Recanati buys 460,000 shares, now holds 8.6% - Stock Titan
Evogene | SCHEDULE 13D/A: Others - Moomoo
Evogene | 4: Statement of changes in beneficial ownership of securities-Director RECANATI LEON - Moomoo
Evogene (EVGN) director Leon Recanati buys 460,000 shares and reports option holdings - Stock Titan
Earnings Preview: Evogene to Report Financial Results Pre-market on August 18 - Moomoo
Leon Recanati Discloses Investment at Evogene Ltd. with 5.7% Stake - TradingView
Evogene (EVGN) director Leon Recanati buys 800,000 shares, lifts stake to 5.7% - Stock Titan
Evogene | SCHEDULE 13D: Others - Moomoo
Evogene Ltd. (EVGN) investor group boosts ownership to 15.98% - Stock Titan
Evogene Ltd (EVGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Evogene (NASDAQ: EVGN) Share Price, EVGN Stock News, EVGN Share Price & Updates - Kalkine
Evogene Ltd. (EVGN) director boosts stake with 800,000-share buy - Stock Titan
ICL and Lavie Bio leverage AI for the development of yield increasing Bio-Stimulants - AgroSpectrum India
Evogene Sets Sept. 4 AGM Amid Board Contest and VP Departure - The Globe and Mail
Evogene Ltd. Revenue Breakdown – NASDAQ:EVGN - TradingView
Evogene (EVGN) Slips 1.2% to $0.48 as Shares Test Narrow Trading RangeMean Reversion Trade - dars.gov.et
Evogene Ltd (EVGN) Struggles Near Support as Selling Pressure PersistsNarrow Range Breakout - dars.gov.et
Evogene Ltd (EVGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Form 13D/A Evogene Ltd. For: 27 July By Investing.com - Investing.com South Africa
Evogene Ltd (EVGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Evogene Ltd. (EVGN) holders report 17.41% stake and new ADS buys - Stock Titan
Evogene Ltd (EVGN) Balance Sheet - TradingKey
EVGN|Evogene Ltd|Price:0.542|Chg%:-0.006 - TradingKey
Evogene Ltd (EVGN) Cash Flow - TradingKey
AI is rewiring future of energy cropsOfer Haviv, CEO, Evogene (EVGN) - AgroSpectrum India
Evogene Ltd Stock (EVGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Evogene Ltd Stock (EVGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RECANATI LEON | Director |
Aug 11 '26 |
Buy |
0.64 |
460,000 |
292,100 |
1,343,886 |
| RECANATI LEON | Director |
Aug 04 '26 |
Buy |
0.50 |
800,000 |
400,000 |
883,886 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):